Categories
Video

Engineering Selective Stability for Activated-Tumor Specific TCBs

Categories
Video

Assaying for Stability of Peptides in Serum

Categories
Video

Affinity Optimization of a Cyclic Peptide

Categories
Video

Discovery Workflow

Categories
Video

History & Technology

Categories
Video

Introduction

Categories
Scientific Publication

Nimble supported collaboration with Roche featured in Nature Communications focus on translational and clinical research.

Nimble’s collaboration with Roche, recently published in Nature Communications as “Protease-activation using anti-idiotypic masks enables tumor specificity of a folate receptor 1-T cell bispecific antibody” has been featured in a focus on translational and clinical research. A link to the articles featured as well as the publication can be found below:

Featured Articles: https://www.nature.com/collections/ecgchegdhe

Publication: https://www.nature.com/articles/s41467-020-16838-w

Categories
Conference

Nimble Therapeutics wraps up 2020 conference attendance, looks forward to 2021

2020 Conferences:

Biocom’s 10th Annual Global Life Science Partnering Conference

Date: February 25-27, 2020
Location: La Jolla, CA
Presentation: Thursday, February 27 @ 10:45 AM Pacific, Charles Fries Room
https://biocomglobalpartnering.org/

BIO Asia (cancelled)

Date: March 10-11, 2020

BIO International

Date: June 8-12, 2020
Location: Virtual
https://www.bio.org/events/bio-digital

Oxford Global Discovery Series: Virtual

Date: July 29-30, 2020
Location: Virtual
https://www.oxfordglobal.co.uk/discovery-series-virtual/

Oxford Global Biologics Series: Virtual

Date: August 27-28, 2020
Location: Virtual
https://www.oxfordglobal.co.uk/biologics-series-virtual/peptides/

Oncology Virtual Partnering

Date: September 22-24, 2020
Location: Virtual
https://virtual-partnering.com/oncology/

BIO Europe

Date: October 26-28, 2020
Location: Virtual
https://informaconnect.com/bioeurope/

Categories
News Partnering Press Release

Nimble Announces Strategic Research Collaboration with Incyte to Discover Novel Peptide-Based Therapeutics

Madison, WI, USA, Oct. 5, 2020 — Nimble Therapeutics Inc. today announced the company has entered into a strategic collaboration with Incyte (NASDAQ: INCY) to discover first-in-class peptide therapies across various disease areas.

“This is an important collaboration for both companies to discover novel peptide based therapeutics,” said Jigar Patel, Ph.D., CEO of Nimble Therapeutics. “We are excited to partner with Incyte, an organization with world-class drug discovery, development and commercialization capabilities, to ensure maximal patient impact across multiple disease indications.”

The collaboration will leverage Nimble’s proprietary peptide synthesis, screening and optimization platform, coupled with its high chemical diversity and integrated suite of assays to enable faster discovery and optimization of promising compounds for intracellular and extracellular targets.

Under the terms of the agreement, Nimble will receive an undisclosed upfront payment, reimbursement of certain research program costs and may become eligible for downstream milestone payments and royalties. Incyte has exclusive rights to develop and commercialize any peptides discovered under the collaboration, and an option to further expand the collaboration to include additional targets.

Categories
Scientific Publication

Protease-activation using anti-idiotypic masks enables tumor specificity of a folate receptor 1-T cell bispecific antibody.

Geiger M, et al. (2020) “Protease-activation using anti-idiotypic masks enables tumor specificity of a folate receptor 1-T cell bispecific antibody.” Nat Commun. 11: 3196. doi: 10.1038/s41467-020-16838-w

Abstract

T-cell bispecific antibodies (TCBs) crosslink tumor and T-cells to induce tumor cell killing. While TCBs are very potent, on-target off-tumor toxicity remains a challenge when selecting targets. Here, we describe a protease-activated anti-folate receptor 1 TCB (Prot-FOLR1-TCB) equipped with an anti-idiotypic anti-CD3 mask connected to the anti-CD3 Fab through a tumor protease-cleavable linker. The potency of this Prot- FOLR1-TCB is recovered following protease-cleavage of the linker releasing the anti-idiotypic anti-CD3 scFv. In vivo, the Prot-FOLR1-TCB mediates antitumor efficacy comparable to the parental FOLR1-TCB whereas a noncleavable control Prot-FOLR1-TCB is inactive. In contrast, killing of bronchial epithelial and renal cortical cells with low FOLR1 expression is prevented compared to the parental FOLR1-TCB. The findings are confirmed for mesothelin as alternative tumor antigen. Thus, masking the anti-CD3 Fab fragment with an anti-idiotypic mask and cleavage of the mask by tumor-specific proteases can be applied to enhance specificity and safety of TCBs.